%0 Journal Article
%T Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases
%A Adriana Valderrama
%A Lonnie Wen
%A Mary E. Costantino
%A Stacey Simmons
%J Archive of "American Health & Drug Benefits".
%D 2019
%X Prostate cancer is the most frequently diagnosed cancer in men in the United States. There is scant real-world evidence characterizing the care utilization and clinical outcomes associated with the use of therapies currently approved by the US Food and Drug Administration (FDA) for patients with metastatic castrate-resistant prostate cancer (CRPC)
%K abiraterone acetate
%K androgen-deprivation therapy
%K bone metastases
%K cabazitaxel
%K docetaxel
%K enzalutamide
%K hormone therapy
%K metastatic castrate-resistant prostate cancer
%K prostate cancer
%K radium-223 dichloride
%K real-world treatment
%K sipuleucel-T
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611520/